Winson Tang Experienced Physician and Researcher

Winson Tang graduated magna cum laude from Tufts University with a four-year combined Bachelor’s and Master’s degree in Organic Chemistry after his family settled in Garden City, New York where they had moved to the United States from Hong Kong. Dr. Tang went on to earn his medical degree from Albert Einstein College of Medicine and completed an Internal Medicine residency at the University of Southern California. He was selected Chief Medical Resident at USC. Dr. Tang also completed his post-doctoral clinical training in Nephrology at the University of California San Diego and started his research career with post-doctoral research training in immunology at the Scripps Research Institute with emphasis on renal immunology, inflammation, and fibrosis.

Winson Tang moved into capital investment after holding positions of increasing responsibility in drug development at Amgen, Tularik, and Isis. He became the Director of Life Science for the Pacific Capital Group in 2006, a private equity group and merchant bank set up to invest the capital of the Winnick family of Southern California in various industries. Dr. Tang was appointed the Chief Operating Officer (COO) of Xcorporeal, Inc. in Los Angeles, a company working on developing a portable hemodialysis machine. During his tenure as COO, the company completed a functional prototype of a portable hemodialysis machine. Xcorporeal was listed on the American Stock Exchange before being acquired by Fresenius AG.

Winson Tang then joined Amsterdam Molecular Therapeutics as a Medical Consultant. He oversaw the conduct of the Phase 2/3 Glybera registration trial for the orphan disease, lipoprotein lipase deficiency. He left the company after completing the clinical section of the MAA that was submitted to the European Medical Association in Dec 2009. Glybera was the first and remains the only gene therapy product approved in the western world. This was one of Dr. Tang’s many contributions to new treatments of deadly diseases around the world.

In early 2010, Winson Tang moved on from Amsterdam Molecular Therapeutics and became the Vice President of Clinical Research for Sangamo Bioscience in Richmond, California. He is responsible for all clinical development programs within the company, including CAR T-cells for glioblastoma, HIV cell therapy, and diabetic neuropathy. His work is critical for the development of much-needed gene and cell therapy treatments that help people suffering from many dangerous maladies throughout the world.

To Learn More About Winson Tang Visit : https://about.me/wtang

PZ Media Inc. is an online marketing agency. This time we are doing writing for 'Stacie Rine' who is the highly successful VP of Business Development of National Aircraft Finance Company about Stacie Rine visit:- https://stacierine.wordpress.com